Qanatpharma is pioneering a new cardiovascular treatment paradigm by targeting microvascular resistance arteries
LYRIC-HF Trial
Lumacafter Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients
A Randomized, Placebo-Controlled, Double-Blind, Phase II Proof-of-Concept Study to Evaluate the Efficacy and Safety of Lumacaftor in Stable Heart Failure Patients with Reduced Ejection Fraction (HFrEF)
Location: St. Michael's Hospital - Toronto, Canada Principal Investigator: Dr. Kim Connelly, MBBS, PhD, FSCMR, FCCS Recruitment: Q2 2026 - Q2 2027
QP's mechanism-based therapeutic strategies target resistance artery dysfunction, which has system-wide consequences - affecting virtually every organ. This strategic focus has widespread application across major diseases with high unmet medical needs.
QP's platform combines unique microvascular datasets, AI-driven target discovery, and a range of disease models for preclinical validation to accelerate drug identification/design.
The term “microcirculation” describes an arrangement of highly specialized blood vessels, ultimately designed to enable the exchange processes that are vital to cell survival.
_
Resistance Arteries
At 10-250 microns in diameter, resistance arteries are main control points located just before the capillaries where the exchange processes occur, regulating organ blood flow and systemic blood pressure.
_
Myogenic Response
Under normal conditions, smooth muscle cells in the vessel wall actively adjust their level of constriction in response to the prevalent pressure level. This key microvascular mechanism, which keeps blood flow constant over a large range of pressures, is termed the “myogenic response” (MR).
_
Microvascular Dysfunction
Microvascular dysfunction (MD) is a primary driver of disease progression and negative clinical outcome. QP’s proprietary approaches focus on mechanism-based treatments that normalize MR to restore normal microvascular function.
Blending academic rigour and industry expertise to advance microvascular medicine
QP's team is based in Canada, Germany, and Switzerland and partners with top scientific and clinical centres to integrate interdisciplinary ideas, technical approaches and methodologies in our work.
.jpg)
